Review of concepts in therapeutic decision‑making in HER2‑negative luminal metastatic breast cancer

• I. Alvarez Lopez ^[1] ; S. Bezares ^[2] ; E. Dalmau Portulas ^[2] ; E. García Martínez ^[2] ; J. Á. García Sáenz ^[2] ; M. Gil Gil ^[2] ; E. Martínez de Dueñas ^[2] ; N. Ribelles ^[2] ; A. Santaballa Bertrán ^[2]
  1. [1] Hospital Universitario Donostia–BioDonostia, Begiristain Doktorea Pasealekua, 109, 20014 Donostia, Gipuzkoa, Spain
  2. [2] Grupo GEICAM de Investigación en Cáncer de Mama/GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 8, 2020, págs. 1364-1377
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Purpose Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti- estrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making.

    Methods This consensus document was generated using a modification of the RAND/UCLA methodology, which included the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 64 medical oncologists specializing in breast cancer.

    Results A Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic decision-making.

    Conclusion We have developed a consensus document with recommendations on the treatment of patients with HER2- negative luminal MBC that will help to improve therapeutic benefits.